N-Acetyl Selank

N-Acetyl Selank is a chemically modified version of Selank, a short synthetic peptide made of seven amino acids in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro ^[1]. Selank was created by attaching a stabilizing fragment to tuftsin, a naturally occurring peptide with immune-regulating properties, and it was developed by Russian researchers at the Institute of Molecular Genetics ^[1]. Adding an acetyl group to the peptide's N-terminus is a common approach meant to slow enzymatic degradation and prolong activity, which is the stated reason for the acetylated form sold on the peptide market. Both are usually presented as solutions for intranasal use.

Selank has been investigated primarily as an anti-anxiety agent. In a Russian comparative clinical study, it produced anxiolytic effects broadly similar to the benzodiazepine medazepam in patients with generalized anxiety disorder and neurasthenia, while also showing antiasthenic and mildly stimulating properties and influencing enkephalin activity in the blood ^[2]. Laboratory work reports additional actions relevant to mood and cognition; intranasal Selank rapidly increased expression of brain-derived neurotrophic factor in the hippocampus of rats, a change linked to neuroplasticity ^[1]. It has also been described as modulating immune signaling and monoamine metabolism, consistent with its tuftsin origin ^[2]. Evidence specific to the N-acetyl derivative is sparse, and most conclusions are extrapolated from the parent peptide.

Selank and its analogs are not approved by major Western regulators and are generally unscheduled; in Russia the parent peptide has seen clinical use. Elsewhere the material circulates as an unapproved research peptide, most often a lyophilized powder or a premixed nasal spray, and gray-market sourcing raises the usual questions about purity and identity. Long-term safety data in humans are limited, and independent large-scale trials are lacking.

Reported side effects are minimal, mainly mild nasal irritation with sprays or occasional drowsiness or headache. It does not appear to cause the dependence or withdrawal seen with benzodiazepines. Long-term and large human safety data are lacking, and material is sold as an unregulated research chemical.

N-Acetyl Selank is a chemically modified version of Selank, a synthetic heptapeptide developed in Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Zakusov Institute of Pharmacology. Selank itself was designed as a stabilized analogue of the endogenous immunopeptide tuftsin, engineered to resist enzymatic breakdown while retaining anxiolytic and neuromodulatory activity. The N-acetylated amidate variant represents a further attempt to improve the peptide's chemical stability and pharmacokinetic behavior, and it circulates primarily as a research-grade compound rather than as an officially approved or extensively published derivative.

N-Acetyl Selank is regarded largely as a peptide of interest to experimenters and the research chemical community rather than a clinically validated agent. Enthusiasts value it for reported calming, anti-anxiety, and mild cognitive effects attributed to the parent Selank, and the acetylated form is often promoted as more stable or longer acting, though such claims rest on limited and mostly informal evidence. Because rigorous human data specific to this variant are scarce and it lacks regulatory approval outside its region of origin, informed users approach it with caution, treating anecdotal reports as suggestive rather than conclusive.